Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gymnemic Acids Stabilize the Yeast Form of Candida albicans and Enhance Action of Antifungal Drugs

By LabMedica International staff writers
Posted on 24 Sep 2013
Small molecules isolated and purified from leaves of the ancient medicinal plant Gymnema sylvestre inhibit yeast-to-hypha conversion and hyphal growth in the fungus Candida albicans, which greatly enhances the effect of antifungal drug treatments.

Candida albicans is a diploid fungus that grows both as yeast and filamentous cells and is a causal agent of opportunistic oral and genital infections in humans. More...
Systemic fungal infections, including those by C. albicans, have emerged as important causes of morbidity and mortality in immunocompromised patients. Furthermore, C. albicans biofilms may form on the surface of implantable medical devices, while hospital-acquired infections by C. albicans have become a cause of major health concerns.

Investigators at Kansas State University (Manhattan, USA) isolated and purified gymnemic acids (GAs) from Gymnema sylvestre. They reported in the September 11, 2013, online edition of the journal PLOS ONE that purified GAs had no effect on the growth and viability of C. albicans yeast cells but inhibited its yeast-to-hypha conversion under several hypha-inducing conditions, including the presence of serum. Moreover, GAs promoted the conversion of C. albicans hyphae into yeast cells under hypha inducing conditions. In a model system, GAs inhibited the formation of invasive hyphae from C. albicans-infected Caenorhabditis elegans worms and rescued the worms from being killed by the fungus.

In addition to their effects on C. albicans, GAs also inhibited conidial germination and hyphal growth of another fungus, Aspergillus.

"We have shown that this compound is safe to use because it does not hurt our body cells, yet it blocks the virulence of this fungus under in vitro conditions," said senior author Dr. Govindsamy Vediyappan, assistant professor of biology at Kansas State University. "Taking the medicine could potentially help patients control the invasive growth of the fungus."

C. albicans also makes a biofilm that can be difficult to treat. The investigators found that the gymnemic acid compounds converted the biofilm back to treatable yeast cells.

"This compound prevents the biofilm formation because hyphae are the major builders of biofilms and biofilms are resistant to antifungals," said Dr. Vediyappan. "Yeast cells by themselves cannot make biofilms and are sensitive to antifungal treatments."

Related Links:
Kansas State University


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.